Status:
COMPLETED
Duration of Platelet Inhibition by Aspirin
Lead Sponsor:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Brief Summary
The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all pat...
Eligibility Criteria
Inclusion
- Patients suffering from stable CAD, on chronic ASA therapy
- Patients willing to participate in the study and to sign the informed consent form
Exclusion
- Acute coronary syndrome or revascularization in the last 3 months prior to enrolment
- Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), clopidogrel, ticlopidine, dipyridamole, warfarin or acenocoumarol
- Frequent use (more than once a week) of non-prescription NSAIDs or drugs containing ASA in the 10 days preceding enrolment
- Major surgical procedure within 1 month before enrolment
- Hemorrhagic diathesis or known platelet dysfunction
- Platelet count outside the 100 to 450 x109/L range for technical reasons
- Hematocrit \< 25% or haemoglobin \< 100 g/L
- Patient undergoing dialysis for chronic renal failure
- Patient found to be ASA resistant
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00671021
Start Date
July 1 2008
End Date
January 1 2009
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada, H4J 1C5